DINESH

Shalby Ltd

Industry: Healthcare
Latest CMP 153
Today's Change ▼ -2.07%
52-Week High / Low 267 | 127
Price Date: 14-Aug-2026
Recommendation Buy
Target Price 208
Expected Upside 16.6%
Forecast Horizon 2 Years
Historical CAGR -2.8%
1,000 Invested 15-Dec-2017
Today's Value 784
Investment Period 9 Years

Stock Snapshot

Post Results Return
-4.8%
Mild Negative Re-rating
1-Year Target Price
178
2-Year Target Price
208
52-Week High / Low
267 / 127
20-Day Return
-7.3%
Market Cap (Cr.)
1,644
Current PE
68.2
P/BV Ratio
1.8
Dividend Yield
0.5%
Industry PE
57.2

Price Performance

Basis of our Recommendation

Shalby Ltd is navigating a complex operational landscape characterized by strong top-line growth in its hospital and implants segments, yet facing margin pressures due to strategic investments and execution challenges. Management's focus on operational leverage and vendor optimization aims to enhance margins, targeting a recovery towards 20% for the hospital business. The recent uptick in hospital occupancy and the break-even milestone at the Sanar facility are positive indicators for revenue growth. However, analysts express caution regarding slower-than-expected margin expansion and increased tax liabilities, which could impact earnings. Vista's forecast reflects stable revenue growth aligned with historical performance, supported by the company's strategic diversification into high-growth specialties and an asset-light expansion model. The healthcare sector's favorable macro conditions, including rising demand for organized care, further bolster Shalby's outlook. Over the next 12-24 months, key opportunities include scaling the implants business and expanding into new markets, while watchpoints include execution risks in the MedTech segment and the profitability of new facilities. Overall, Vista anticipates a 13% upside, with a target price of 173.0, reflecting a fair valuation amidst cautious investor sentiment

👍 Why We Like This Stock

  • Strong top-line growth in hospital and implants segments, indicating robust demand
  • Management's strategic focus on operational leverage and vendor optimization to enhance margins
  • Expansion into high-growth specialties and asset-light models to drive future revenue

Things To Watch Out For

  • Margin pressures from strategic investments and execution challenges in the MedTech business
  • Cautious analyst sentiment regarding slower-than-anticipated margin expansion
  • Increased tax liabilities impacting earnings forecasts

Key Parameters

Balance Sheet Strength
Stable Financial Structure
Market Share
Stable
Industry Outlook
Stable
Analyst View
Hold
Dividend History
Regular
FII Holdings
Stable

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 934 1,087 1,141 1,193 1,322
Profit Before Tax (Cr.) 119 47 61 40 54
PBT Margin 12.7% 4.3% 534.6% 3.3% 4.1%
Net Profit (Cr.) 64 1 23 30 35
Earnings Per Share 6.1 0.4 2.4 2.4 3.3

Analyst Recommendations

Broker Recommendation Target Price Date
Elara Capital ► Accumulate 173 14-Aug-2026
Consensus Recommendation ► Hold
Consensus Target 173
Coverage 1 Analysts
Analysts' Viewpoint
Shalby Ltd is experiencing robust growth in its hospital and implants segments, with hospital occupancy and international patient contributions improving significantly. However, margin pressure from upfront investments and modest profitability in the MedTech segment present challenges. Analysts express caution due to slower-than-anticipated margin expansion and higher tax liabilities. Management's focus on operating leverage and tariff revisions aims to drive margin recovery, while upcoming payer tariff revisions and facility performance improvements are anticipated to support future growth.

Company Overview

Show Company Profile

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.